US4652522A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Continuous lymphocyte cell lines, their production and use
Assignee: University of Pennsylvania
•
Filing: 1983-07-05
•
Granted: 1987-03-24
•
Expires: 2003-07-05
Abstract
Abstract A method for producing continuous B lymphocyte cell lines and monoclonal antibodies by such lines is provided. DNA isolated from neoplastic cells is introduced into stimulated lymphocytes. Individual cells that have been transformed by the added DNA and that produce antibodies are clonally expanded. Cultures of these continuous cells are employed to produce monoclonal antibodies.
Inventors
- 👤 Roger H. Kennett
- 👤 Zdenka L. Jonak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 01:47
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/87; C07; C07K; C07K16/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
65 words
A method of producing a continuous lymphocyte cell line comprising: (a) providing normal, stimulated B lymphocytes; (b) transfecting said lymphocytes with exogenous DNA isolated from a neoplastic cell, said DNA having the ability to transform lymphocytes; (c) recovering from said transfected lymphocytes a transformed lymphocyte; and (d) clonally expanding said transformed lymphocyte to a continuous cell line that stably maintains the production of monoclonal antibodies.
Claim 2
Independent Claim
65 words
A method of producing a continuous lymphocyte cell line comprising: (a) providing normal, stimulated B lymphocytes; (b) transfecting said lymphocytes with exogenous DNA isolated from a neoplastic cell, said DNA having the ability to transform lymphocytes; (c) recovering from said transfected lymphocytes a transformed lymphocyte; and (d) clonally expanding said transformed lymphocyte to a continuous cell line that stably maintains the production of monoclonal antibodies.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein said normal, stimulated B lymphocytes are human lymphocytes.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein said normal, stimulated lymphocytes are mouse lymphocytes.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said neoplastic cell is a malignant lymphocyte.
Claim 6
Dependent Claim
13 words
The method of claim 2 wherein said neoplastic cell is a malignant lymphocyte.
Claim 7
Dependent Claim
13 words
The method of claim 3 wherein said neoplastic cell is a malignant lymphocyte.
Claim 8
Dependent Claim
14 words
The method of claim 1 wherein said neoplastic cell is a malignant B lymphocyte.
Claim 9
Dependent Claim
14 words
The method of claim 2 wherein said neoplastic cell is a malignant B lymphocyte.
Claim 10
Dependent Claim
14 words
The method of claim 3 wherein said neoplastic cell is a malignant B lymphocyte.
Claim 11
Dependent Claim
14 words
The method of claim 1 wherein said neoplastic cell is a Reh leukemia cell.
Claim 12
Dependent Claim
14 words
The method of claim 2 wherein said neoplastic cell is a Reh leukemia cell.
Claim 13
Dependent Claim
14 words
The method of claim 3 wherein said neoplastic cell is a Reh leukemia cell.
Claim 14
Dependent Claim
34 words
The method of claim 1 wherein said transfection comprises treatment of said normal, stimulated B lymphocytes with a calcium phosphate DNA coprecipitate in conjunction with treatment of said lymphocytes with polyethylene glycol and dimethylsulfoxide.
Claim 15
Dependent Claim
34 words
The method of claim 2 wherein said transfection comprises treatment of said normal, stimulated B lymphocytes with a calcium phosphate DNA coprecipitate in conjunction with treatment of said lymphocytes with polyethylene glycol and dimethylsulfoxide.
Claim 16
Dependent Claim
34 words
The method of claim 3 wherein said transfection comprises treatment of said normal, stimulated B lymphocytes with a calcium phosphate DNA coprecipitate in conjunction with treatment of said lymphocytes with polyethylene glycol and dimethylsulfoxide.
Claim 17
Dependent Claim
13 words
A continuous, stable, antibody-producing cell line produced by the method of claim 1.
Claim 18
Dependent Claim
13 words
A continuous, stable, antibody-producing cell line produced by the method of claim 2.
Claim 19
Dependent Claim
13 words
A continuous, stable, antibody-producing cell line produced by the method of claim 3.
Claim 20
Dependent Claim
18 words
A biologically pure culture of the continuous, stable, antibody-producing cell line produced by the method of claim 1.
Claim 21
Dependent Claim
23 words
A method of producing monoclonal antibodies comprising growing the cell line of claim 16 and recovering the antibodies produced by said cell line.
Claim 22
Dependent Claim
23 words
A method of producing monoclonal antibodies comprising growing the cell line of claim 17 and recovering the antibodies produced by said cell line.
Claim 23
Dependent Claim
23 words
A method of producing monoclonal antibodies comprising growing the cell line of claim 18 and recovering the antibodies produced by said cell line.
References Cited (Backward Citations)
US4001080A
Cited
US4108983A
Cited
US4195074A
Cited
US4196265A
Cited
US4172124A
Cited
US4271145A
Cited
US4332893A
Cited
US4334016A
Cited
EP0057107A2
Cited
US4565687A
Cited
US4464465A
Cited
US4529694A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-03-23 | 1990-09-22 | 1991-03-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-03-23 | 1994-09-22 | 1995-03-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-03-23 | 1998-09-22 | 1999-03-24 | $7700.00 | Window Closed / Lapsed |